<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dicloxacillin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dicloxacillin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dicloxacillin: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12374" href="/d/html/12374.html" rel="external">see "Dicloxacillin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13227" href="/d/html/13227.html" rel="external">see "Dicloxacillin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F159525"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Penicillin</li></ul></div>
<div class="block doa drugH1Div" id="F159496"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41e7128d-0c0e-4cf4-a89d-c764ca1459d8">Endocarditis, treatment, oral-step down therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment, oral-step down therapy: Note: </b>Not first-line therapy; data are limited. Reserve use for patients who inject drugs who had initial clinical improvement with IV treatment for methicillin-susceptible <i>S. aureus</i> infection but cannot complete IV standard of care therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414','lexi-content-ref-30152252','lexi-content-ref-35139280','lexi-content-ref-36052413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414','lexi-content-ref-30152252','lexi-content-ref-35139280','lexi-content-ref-36052413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 1 g 4 times daily in combination with rifampin for a total duration, including initial IV therapy, of 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414','lexi-content-ref-30152252']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414','lexi-content-ref-30152252'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1378dcb0-a2fc-424f-8753-558943d5f1e0">Mastitis, lactational</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mastitis, lactational: Oral: </b>500 mg 4 times daily for 10 to 14 days; shorter courses (eg, 5 to 7 days) may be considered for patients with rapid clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35576513','lexi-content-ref-Dixon.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35576513','lexi-content-ref-Dixon.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection (alternative agent):</b> Oral continuation therapy for methicillin-susceptible <i>S. aureus</i> (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 500 mg 3 or 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>). <b>Note:</b> Duration ranges from a minimum of 3 months to indefinitely, depending on patient-specific factors. For the first 3 to 6 months of therapy, combine with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.1','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.1','lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not an appropriate agent if methicillin-resistant <i>S. aureus</i> is suspected or confirmed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2','lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2','lexi-content-ref-24973422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Cellulitis (nonpurulent)/erysipelas, mild:</b>
<b>Oral:</b> 500 mg 4 times daily for 5 days; duration may be extended up to 14 days if not resolved/slow response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422','lexi-content-ref-Spelman.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422','lexi-content-ref-Spelman.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Impetigo or ecthyma: Note: </b>For impetigo, reserve systemic therapy for patients with numerous lesions or in outbreak settings to decrease transmission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 250 to 500 mg 4 times daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2','lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2','lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990084"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no specific dosage adjustments provided in the manufacturer's labeling; a reduction in total dosage should be considered in renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Not dialyzable; supplemental dose is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis effects: Supplemental dose is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987356"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. </p></div>
<div class="block doe drugH1Div" id="F159497"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F159512"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13227" href="/d/html/13227.html" rel="external">see "Dicloxacillin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing</b>: Infants, Children, and Adolescents: Oral: 3 to 6.25 mg/kg/dose every 6 hours; maximum dose: 250 mg/dose. Higher doses are recommended for some infections (eg, osteoarticular infections, skin and soft tissue infections) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2022','lexi-content-ref-AAP.2021','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2022','lexi-content-ref-AAP.2021','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12a27a5a-a2e0-47a9-83f0-dca4453f8443">Osteoarticular infection; eg, septic arthritis, osteomyelitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoarticular infection; eg, septic (bacterial) arthritis, osteomyelitis:</b>
<i>Step-down therapy following parenteral treatment: </i></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 25 mg/kg/dose every 6 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2022','lexi-content-ref-430319','lexi-content-ref-28708801','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2022','lexi-content-ref-430319','lexi-content-ref-28708801','lexi-content-ref-AAP.2021'])">Ref</a></span>). Minimum total duration is 2 to 3 weeks for septic arthritis and 3 to 4 weeks for osteomyelitis; however, duration is often longer and individualized based on several factors, including causative pathogen, response to therapy, and normalization of inflammatory markers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28708801','lexi-content-ref-34350458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28708801','lexi-content-ref-34350458'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1e19befb-2ea0-4673-a9a2-32054d50ef8e">Skin and soft tissue infection, methicillin-susceptible <i>Staphylococcus aureus</i></span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection, methicillin-susceptible </b>
<i>
<b>Staphylococcus aureus</b></i>
<b> (MSSA):</b> Infants, Children, and Adolescents: Oral: 6.25 to 12.5 mg/kg/dose every 6 hours; maximum dose: 500 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24973422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24973422'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109223"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: There are no specific dosage adjustments provided in the manufacturer’s labeling; a reduction in total dosage should be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Not dialyzable.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Not dialyzable.</p></div>
<div class="block dohp drugH1Div" id="F51109224"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F159466"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for dicloxacillin.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin photosensitivity (acute exanthematous pustulosis; Nielsen 2020), skin rash (Drivenes 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (Johnson 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Cholestasis (Gosbell 2000), <i>Clostridioides difficile</i> colitis, diarrhea, esophageal ulcer, esophagitis, hairy tongue, heartburn, melanoglossia, nausea, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, anemia, eosinophilia, granulocytopenia, hemolytic anemia, leukopenia, neutropenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Kleinman 1986), hepatotoxicity (Gosbell 2000), increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema, serum sickness-like reaction, type 1 hypersensitivity reaction and type IV hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (Gosbell 2000), renal insufficiency (Gosbell 2000), renal tubular disease</p></div>
<div class="block coi drugH1Div" id="F159478"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;">Hypersensitivity to dicloxacillin, other penicillins, or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F159463"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have been reported in patients on penicillin therapy. Initiate therapy only after a comprehensive drug and allergy history; use with caution in patients with a history of significant allergies and/or asthma. Discontinue use and institute appropriate therapy if a hypersensitivity reaction occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p></div>
<div class="block foc drugH1Div" id="F159474"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p></div>
<div class="block geq drugH1Div" id="F159459"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F3422221"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Dicloxacillin Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $1.38 - $1.50</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $2.51 - $2.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F803125"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer 1 hour before or 2 hours after meals with at least 120 mL of water. Should not be administered in the supine position or immediately before going to bed.</p></div>
<div class="block admp drugH1Div" id="F52612542"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with water 1 hour before or 2 hours after meals with at least 120 mL (4 ounces) of water; should not be administered in the supine position or immediately before going to bed.</p></div>
<div class="block use drugH1Div" id="F159475"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Staphylococcal infections:</b> Treatment of infections caused by penicillinase-producing staphylococci. </p></div>
<div class="block mst drugH1Div" id="F54703985"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Dicloxacillin, when used in neonates, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be used with caution due to risk of kernicterus (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F159519"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3; <b>Induces</b> CYP2C19 (moderate), CYP2C9 (weak), CYP3A4 (weak)</p></div>
<div class="block dri drugH1Div" id="F159468"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Abrocitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Penicillins may decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Brivaracetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carisoprodol: CYP2C19 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Carisoprodol. CYP2C19 Inducers (Moderate) may decrease the serum concentration of Carisoprodol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Weak) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP2C19 Inducers (Moderate) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Penicillins may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Weak) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Penicillins may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Weak) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Omeprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Dicloxacillin may decrease the serum concentration of Ospemifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Weak) may decrease the serum concentration of Selpercatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Weak) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Benzoate: Penicillins may diminish the therapeutic effect of Sodium Benzoate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May diminish the therapeutic effect of Penicillins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Weak) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Dicloxacillin may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: CYP2C19 Inducers (Moderate) may decrease the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F159488"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases drug absorption rate and serum concentration. Management: Administer on an empty stomach with a large glass of water 1 hour before or 2 hours after meals.</p></div>
<div class="block pri drugH1Div" id="F5720683"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Dicloxacillin crosses the placenta (Depp 1970; MacAulay 1968; Seiga 1974).</p>
<p style="text-indent:0em;margin-top:2em;">Penicillin class antibiotics cross the placenta in varying degrees. Dicloxacillin is highly protein bound, which may influence fetal exposure (Nau 1987).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).</p></div>
<div class="block brc drugH1Div" id="F159480"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Dicloxacillin is present in breast milk (Matsuda 1984; Muysson 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of dicloxacillin in breast milk has been located from 2 studies.</p>
<p style="text-indent:-2em;margin-left:4em;">• A single oral dose of dicloxacillin 250 mg was administered to 2 or 3 women 5 to 7 days postpartum. Breast milk concentrations were ≤0.3 mcg/mL over a 6-hour period, with the highest concentrations observed 4 hours after the maternal dose. In contrast, the highest maternal serum concentration (5.2 mcg/mL) was found 1 hour after the dose, decreasing to ≤0.4 mcg/mL 6 hours after the dose (Matsuda 1984). Using a breast milk concentration of 0.3 mcg/mL, the relative infant dose (RID) of dicloxacillin is 0.09% to 0.18% compared to an infant therapeutic dose of 25 to 50 mg/kg/day, providing an estimated daily infant dose via breast milk of 0.045 mg/kg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">• The RID of dicloxacillin was calculated by the authors of a second study following multiple doses for the treatment of mastitis. Included were 3 women, 1 to 6 months postpartum, receiving dicloxacillin 500 mg every 6 hours; breast milk was sampled at intervals from 0 to 6 hours after the maternal dose on or after the fourth day of therapy. The highest breast milk concentration was 0.0676 mcg/mL, which occurred 4 hours after the maternal dose. Authors of the study calculated the RID of dicloxacillin to be 0.03% of the weight-adjusted maternal dose, providing an estimated daily dose of 0.008 mg/kg/day via breast milk (Muysson 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">In general, antibiotics that are present in breast milk may cause non–dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">Although the manufacturer recommends that caution be exercised when administering dicloxacillin to patients who are breastfeeding, penicillins are considered compatible with breastfeeding when used in usual recommended doses (WHO 2002).</p>
<p style="text-indent:-2em;margin-left:2em;">Dicloxacillin is a recommended antibiotic for the empiric treatment of bacterial mastitis in patients who are breastfeeding. Antibiotic use may be considered when symptoms are present for &gt;24 hours and have not responded to conservative measures, or the patient has symptoms such as fever or tachycardia. Consider a milk culture if symptoms do not improve after 48 hours of antibiotic therapy. The diagnosis of mastitis does not require interruption of breastfeeding (ABM [Mitchell 2022]; WHO 2000).</p></div>
<div class="block mop drugH1Div" id="F159472"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Baseline and periodic CBC with differential; periodic BUN, serum creatinine, AST and ALT (especially with prolonged therapy); prothrombin time if patient concurrently on warfarin; signs of anaphylaxis during first dose</p></div>
<div class="block pha drugH1Div" id="F159462"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F159477"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and incomplete; reduced by food.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: CSF penetration is low.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: 0.295 ± 0.092 L/kg (range: 0.08 to 0.512 L/kg) (Smith 1990).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: 5.99 L; increased in patients with ESRD on IHD (Nauta 1976).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 95% to 99% (primarily albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: 59.89% ± 24.44% (Smith 1990).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 49% to 76% (Nauta 1976).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: 32 minutes (Smith 1990).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~0.7 hours; prolonged with renal impairment (Nauta 1976).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: 1.68 ± 0.84 hours (range: 0.58 to 3.7 hours) (Smith 1990).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1 to 1.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces; urine (as unchanged drug):</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">CF patients: More rapid excretion than healthy patients (Jusko 1975).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F159482"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Diclocil</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Diclocil | Dicloxacillin mylan | Dicloxsig | Distaph</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Diclox</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bamaxin | Beciprof | Clobetcina | Cloxidin | Cloxil | Damacir | Diclocil | Diclogran | Diclomax | Diclosan | Diclotin | Diclovert | Diclox | Dicloxacilina | Dixalin | Dixapidin | Impo diclox | Masdiclox | Odontocil | Prediclex | Servidiclox | Xalin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Infectostaph</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Diclocil | Dicloxacilina | Dicloxacilina Alfa | Ditterolina | Dixalin | Posipen | Xalin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cloxagen | Cloxin | Diclocil | Dicloxacilina | Dicloxacilina MK | Dicloxacilina R | Dicloxen | Dicloxina | Dixalin | H.G. Dicloxacil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Diclocil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Diclocil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Diclocil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Odicoza | Quali-Dicloxin | Ziefmycin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Diclopen | Dicloxacillin | Dynapen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Klox D</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Staklox</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Diclex | Staphcillin a</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Diclocil</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Amifarin | Antiben | Brispen | Butimaxil | Clomicin | Coxaclan | Diamsalina | Dic fhi | Dicleophen | Diclotecno | Dicloxacil. gi | Dicloxacili.gi mer | Dicloxacilina | Dicloxacilina gi d | Dicloxacilina GI S | Dicloxacilina landsteiner | Dicloxacillin | Dicloxaquim | Dimicin | Ditterolina | Dixen | Doxil | Iclox | Ormopen | Penclox | Posipen | Xozacil</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dicillin | Diclin | Diclocil | Dicloxacillin alternova | Dicloxacillin bluefish | Dicloxacillin orion</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Diclocil</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dermicilina | Diclobact | Diclocil | Diclomax | Dicloxacilina | Dicloxal | Dicloxil | Dicloxina | Dilovet | Dinapen | Dyclobiot | Plicben | Posipen | Vacloxipen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dicloxacillin | Dicloxacillin sodium | Dynapen</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Diclocil</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Diclocil | Dikloxacillin AstraZeneca | Dikloxacillin meda</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Amcidil | Clox med | Cloxydin | D cloxa | Deoclox | Dicapzo | Dicillin | Diclex | Diclocil | Diclocillin | Diclohof | Diclomed | Diclonox | Dicloson | Diclox | Dicloxa | Dicloxacillin | Dicloxane | Dicloxapen | Dicloxgen | Dicloxhim | Dicloxia | Dicloximed | Dicloxin | Dicloxlin | Dicloxman | Dicloxno | Dicloxpac | Diloxin | Dimocin | Dixalin | Dixocillin | Dorox | Kressdixa | Madiclox | Phardicin | Servidiclox | Staphocil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dacocilin | Diclocil | Diclocin | Diclox | Dicloxacillin | Ziefmycin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Diclocil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27891788">
<a name="27891788"></a>Ailes EC, Gilboa SM, Gill SK, et al. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. <i>Birth Defects Res A Clin Mol Teratol</i>. 2016;106(11):940-949. doi:10.1002/bdra.23570<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/27891788/pubmed" id="27891788" target="_blank">27891788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics. Dicloxacillin. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2">
<a name="Baddour.2"></a>Baddour LM. Impetigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.1">
<a name="Baddour.1"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36043414">
<a name="36043414"></a>Baddour LM, Weimer MB, Wurcel AG, et al; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease. Management of infective endocarditis in people who inject drugs: a scientific statement from the American Heart Association. <i>Circulation</i>. 2022b;146(14):e187-e201. doi:10.1161/CIR.0000000000001090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/36043414/pubmed" id="36043414" target="_blank">36043414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26598097">
<a name="26598097"></a>Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. <i>Pharmacotherapy</i>. 2015;35(11):1052-1062. doi:10.1002/phar.1649<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/26598097/pubmed" id="26598097" target="_blank">26598097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2022">
<a name="Bradley.2022"></a>Bradley JS, Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-430319">
<a name="430319"></a>Bryson YJ, Connor JD, LeClerc M, Giammona ST. High-dose oral dicloxacillin treatment of acute staphylococcal osteomyelitis in children. <i>J Pediatr</i>. 1979;94(4):673-675. doi:10.1016/s0022-3476(79)80049-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/430319/pubmed" id="430319" target="_blank">430319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884587">
<a name="19884587"></a>Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/19884587/pubmed" id="19884587" target="_blank">19884587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31260651">
<a name="31260651"></a>Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. <i>Am J Obstet Gynecol</i>. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/31260651/pubmed" id="31260651" target="_blank">31260651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5429971">
<a name="5429971"></a>Depp R, Kind AC, Kirby WM, Johnson WL. Transplacental passage of methicillin and dicloxacillin into the fetus and amniotic fluid. <i>Am J Obstet Gynecol</i>. 1970;107(7):1054-1057. doi:10.1016/0002-9378(70)90628-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/5429971/pubmed" id="5429971" target="_blank">5429971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Dicloxacillin [prescribing information]. Princeton, NJ: Sandoz Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dixon.2022">
<a name="Dixon.2022"></a>Dixon JM. Lactational mastitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3277054">
<a name="3277054"></a>Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/3277054/pubmed" id="3277054" target="_blank">3277054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35079385">
<a name="35079385"></a>Drivenes JL, Berg-Jensen M, Bygum A. A phototoxic drug reaction due to topical NSAIDs. <i>Clin Case Rep</i>. 2022;10(1):e05251. doi:10.1002/ccr3.5251<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/35079385/pubmed" id="35079385" target="_blank">35079385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11149309">
<a name="11149309"></a>Gosbell IB, Turnidge JD, Tapsall JW, Benn RA. Toxicities of flucloxacillin and dicloxacillin--is there really a difference?. <i>Med J Aust</i>. 2000;173(9):500-501.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/11149309/pubmed" id="11149309" target="_blank">11149309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30152252">
<a name="30152252"></a>Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. <i>N Engl J Med</i>. 2019;380(5):415-424. doi:10.1056/NEJMoa1808312<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/30152252/pubmed" id="30152252" target="_blank">30152252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12088358">
<a name="12088358"></a>Johnson DW, Kay TD, Hawley CM. Severe hypokalaemia secondary to dicloxacillin. <i>Intern Med J</i>. 2002;32(7):357-358. doi:10.1046/j.1445-5994.2002.00243.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/12088358/pubmed" id="12088358" target="_blank">12088358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1196754">
<a name="1196754"></a>Jusko WJ, Mosovich LL, Gerbracht LM, et al. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. <i>Pediatrics.</i> 1975; 56(6): 1038-1044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/1196754/pubmed" id="1196754" target="_blank">1196754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3701014">
<a name="3701014"></a>Kleinman MS, Presberg JE. Cholestatic hepatitis after dicloxacillin-sodium therapy. <i>J Clin Gastroenterol</i>. 1986;8(1):77-78. doi:10.1097/00004836-198602000-00017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/3701014/pubmed" id="3701014" target="_blank">3701014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25189188">
<a name="25189188"></a>Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. <i>Expert Opin Drug Saf</i>. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/25189188/pubmed" id="25189188" target="_blank">25189188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5699769">
<a name="5699769"></a>MacAulay MA, Berg SR, Charles D. Placental transfer of dicloxacillin at term. <i>Am J Obstet Gynecol</i>. 1968;102(8):1162-1168. doi:10.1016/0002-9378(68)90407-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/5699769/pubmed" id="5699769" target="_blank">5699769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6743732">
<a name="6743732"></a>Matsuda S. Transfer of antibiotics into maternal milk.<i> Biol Res Pregnancy Perinatol</i>. 1984;5(2):57-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/6743732/pubmed" id="6743732" target="_blank">6743732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>Key Potentially Inappropriate Drugs in Pediatrics:</i> The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576513">
<a name="35576513"></a>Mitchell KB, Johnson HM, Rodríguez JM, et al; Academy of Breastfeeding Medicine. Academy of Breastfeeding Medicine clinical protocol #36: the mastitis spectrum, revised 2022. <i>Breastfeed Med</i>. 2022;17(5):360-376. doi:10.1089/bfm.2022.29207.kbm<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/35576513/pubmed" id="35576513" target="_blank">35576513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28722171">
<a name="28722171"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. <i>Br J Clin Pharmacol</i>. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/28722171/pubmed" id="28722171" target="_blank">28722171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28461374">
<a name="28461374"></a>Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. <i>CMAJ</i>. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/28461374/pubmed" id="28461374" target="_blank">28461374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32678981">
<a name="32678981"></a>Muysson M, Datta P, Rewers-Felkins K, Baker T, Hale TW. Transfer of dicloxacillin into human milk. <i>Breastfeed Med</i>. Published online July 15, 2020. doi:10.1089/bfm.2020.0156<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/32678981/pubmed" id="32678981" target="_blank">32678981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3301235">
<a name="3301235"></a>Nau H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. <i>Dev Pharmacol Ther</i>. 1987;10(3):174-198. doi:10.1159/000457744<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/3301235/pubmed" id="3301235" target="_blank">3301235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1277730">
<a name="1277730"></a>Nauta EH, Mattie H. Dicloxacillin and cloxacillin: pharmacokinetics in healthy and hemodialysis subjects. <i>Clin Pharm and Ther.</i> 1976;20(1): 98-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/1277730/pubmed" id="1277730" target="_blank">1277730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32185054">
<a name="32185054"></a>Nielsen RM, Pallesen KA. Photoinduced acute exanthematous pustulosis caused by dicloxacillin and exposure to sunlight. <i>Clin Case Rep</i>. 2020;8(3):538-539. Published 2020 Feb 14. doi:10.1002/ccr3.2681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/32185054/pubmed" id="32185054" target="_blank">32185054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al, “Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,” <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3429065">
<a name="3429065"></a>Pacifici GM, Viani A, Taddeucci-Brunelli G, et al, “Plasma Protein Binding of Dicloxacillin: Effects of Age and Diseases,” <i>Int J Clin Pharmacol Ther Toxicol</i>, 1987, 25(11):622-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/3429065/pubmed" id="3429065" target="_blank">3429065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35139280">
<a name="35139280"></a>Pries-Heje MM, Wiingaard C, Ihlemann N, et al. Five-year outcomes of the partial oral treatment of endocarditis (POET) trial. <i>N Engl J Med</i>. 2022;386(6):601-602. doi:10.1056/NEJMc2114046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/35139280/pubmed" id="35139280" target="_blank">35139280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708801">
<a name="28708801"></a>Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. <i>Pediatr Infect Dis J</i>. 2017;36(8):788-799. doi:10.1097/INF.0000000000001635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/28708801/pubmed" id="28708801" target="_blank">28708801</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4436958">
<a name="4436958"></a>Seiga K, Yamaji K, Sugiyama Y. Distribution of ampicillin-dicloxacillin combination in the body. Article in Japanese, author's translation. <i>Jpn J Antibiot</i>. 1974;27(4):494-496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/4436958/pubmed" id="4436958" target="_blank">4436958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2311479">
<a name="2311479"></a>Smith AL, Meeks CA, Koup JR, Opheim KE, Weber A, Vishwanathan CT. Dicloxacillin absorption and elimination in children. <i>Dev Pharmacol Ther</i>. 1990;14(1):35-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/2311479/pubmed" id="2311479" target="_blank">2311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.2022">
<a name="Spelman.2022"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24973422">
<a name="24973422"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/24973422/pubmed" id="24973422" target="_blank">24973422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36052413">
<a name="36052413"></a>Wildenthal JA, Atkinson A, Lewis S, et al. Outcomes of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in people who inject drugs. <i>Clin Infect Dis</i>. 2023;76(3):487-496. doi:10.1093/cid/ciac714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/36052413/pubmed" id="36052413" target="_blank">36052413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34350458">
<a name="34350458"></a>Woods CR, Bradley JS, Chatterjee A, et al. Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. <i>J Pediatric Infect Dis Soc</i>. 2021;10(8):801-844. doi:10.1093/jpids/piab027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/34350458/pubmed" id="34350458" target="_blank">34350458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization. (‎2000)‎. Mastitis: causes and management. World Health Organization. https://apps.who.int/iris/handle/10665/66230
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. Published 2002. https://apps.who.int/iris/handle/10665/62435
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10090000">
<a name="10090000"></a>Wright AJ, “The Penicillins,” <i>Mayo Clin Proc</i>, 1999, 74(3):290-307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dicloxacillin-drug-information/abstract-text/10090000/pubmed" id="10090000" target="_blank">10090000</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9349 Version 267.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
